Sequential Therapies After Osteoanabolic Treatment

Recruiting now

Conditions studied: Osteoporosis, Postmenopausal

In brief

12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics

Key facts

Study ID: NCT06164795
Run by: 424 General Military Hospital
People needed: 150
Starts: 2023-11-25
Expected to finish: 2027-12-01
Last updated by the study team: 2026-07-22

Who can join

Age: 50 and older, up to 85. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Postmenopausal women treated with severe osteoporosis completing their course with romosozumab or teriparatide

You may not qualify if…

a bone disease other than postmenopausal osteoporosis
use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study
creatinine clearance <60 mL/min/1.73 m2
liver failure
any type of cancer
uncontrolled endocrine diseases
serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng/mL (50 nmol/L)
hypersensitivity to denosumab or zoledronate or teriparatide or romosozumab or any of the excipients

Where it is running

251 Airforce & VA General Hospital — Athens, Greece (enrolling)
First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens — Athens, Greece (enrolling)
, KAT General Hospital — Athens, Greece (enrolling)
424 General Military Hospital — Thessaloniki, Greece (enrolling)
Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico — Milan, Italy (enrolling)
Campus Bio-Medico University — Roma, Italy (enrolling)
Department of Medicine, Surgery and Neurosciences, University of Siena — Siena, Italy (enrolling)
University-Hospital S. Maria della Misericordia — Udine, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.